An observational study in Cardiomyopathy, sponsored by University Health Network, Toronto. Completed at 1 site in Canada. Per ClinicalTrials.gov, last updated 2019-10-02.
Sponsored by University Health Network, Toronto · Observational
This study will evaluate the prognostic utility of novel ECG markers of electrical instability in patients with cardiomyopathy.
Baseline ECG markers of electrical instability will be measured in patients with cardiomyopathy. These ECG markers will be evaluated from a clinical Holter recording. All patients will have a primary implantable cardioverter defibrillator (ICD) as part of their clinical care. Patients will be followed prospectively for 2 years to evaluate the primary outcome of appropriate ICD shocks. Multivariable modelling will be performed to determine whether the ECG markers of electrical instability independently predict the primary clinical outcome.
1,176 studies on the registry are indexed under Cardiomyopathies; 287 are open to participants now.
This study's enrollment of 164 is close to the median of 153 across 515 observational studies indexed under Cardiomyopathies.
Browse Cardiomyopathies studies →University Health Network, Toronto is the lead sponsor of 1,411 studies on the registry; 292 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with cardiomyopathy and primary prevention ICDs
Exclusion Criteria:
Proportion of patients with appropriate implantable cardioverter defibrillator (ICD) shocks
Proportion is from 0 (no patients with shocks) to 100% (all patients receive shocks)
Time frame: 2 years
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto